Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia

Completed · Phase 3

Conditions studied: Hypercholesterolemia, Familial, Hyperlipidemia

In brief

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of torcetrapib/atorvastatin compared to atorvastatin alone in patients with heterozygous familial hypercholesterolemia

Key facts

Study ID

NCT00134485

Run by

Pfizer

People needed

400

Starts

2005-03-01

Expected to finish

2006-03-01

Last updated by the study team

2007-10-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Heterozygous Familial Hypercholesterolemia
• At least 18 years of age

You may not qualify if…

• Women who are pregnant or lactating, or planning to become pregnant.
• Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid (high doses)
• Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
• Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study

Where it is running

• Pfizer Investigational Site — San Diego, California, United States
• Pfizer Investigational Site — Washington D.C., District of Columbia, United States
• Pfizer Investigational Site — Lutz, Florida, United States
• Pfizer Investigational Site — Tampa, Florida, United States
• Pfizer Investigational Site — Tripler AMC, Hawaii, United States
• Pfizer Investigational Site — Chicago, Illinois, United States
• Pfizer Investigational Site — Indianapolis, Indiana, United States
• Pfizer Investigational Site — Iowa City, Iowa, United States
• Pfizer Investigational Site — Auburn, Maine, United States
• Pfizer Investigational Site — Scarborough, Maine, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Charlotte, North Carolina, United States
• Pfizer Investigational Site — Houston, Texas, United States
• Pfizer Investigational Site — Madison, Wisconsin, United States
• Pfizer Investigational Site — Camperdown, New South Wales, Australia
• Pfizer Investigational Site — Woolloongabba, Queensland, Australia
• Pfizer Investigational Site — North Adelaide, South Australia, Australia
• Pfizer Investigational Site — Clayton, Victoria, Australia
• Pfizer Investigational Site — Perth, Western Australia, Australia
• Pfizer Investigational Site — Darlinghurst, Australia
• Pfizer Investigational Site — Chicoutimi, Quebec, Canada
• Pfizer Investigational Site — Montreal, Quebec, Canada
• Pfizer Investigational Site — Montreal, Quebec, Canada
• Pfizer Investigational Site — Ste-Foy, Quebec, Canada
• Pfizer Investigational Site — Aalborg, Denmark

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.